Loading clinical trials...

Immune Responses to COVID-19 Vaccination in Lymphoma Patients | Clinical Trials | Clareo Health

COMPLETED

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

PROSECO - A UK Multicentre Prospective Observational Study Evaluating COVID-19 Vaccine Immune Responses in Lymphoid Cancer

NCT04858568•University Hospital Southampton NHS Foundation Trust

View on ClinicalTrials.gov

Summary

This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in vaccinated individuals. To do this, we will collect peripheral blood from patients with lymphoid cancers before and after their COVID-19 vaccination. The blood will be explored in the laboratory for antibodies to SARS-CoV-2 and T-cell responses to the spike protein. Detailed clinical information will also be collated on about their cancer and treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients having a confirmed diagnosis of either:
•A) Hodgkin lymphoma B) Aggressive B-cell lymphoma (e.g. Burkitt's lymphoma, diffuse large B-cell lymphoma, grade 3b follicular lymphoma, de novo transformed follicular lymphoma) C) Indolent B-cell lymphoma (e.g. all grades of follicular lymphoma except grade 3b, marginal zone lymphoma, lymphoplasmacytic lymphoma, chronic or small lymphocytic lymphoma, mantle cell lymphoma) D) Mature T/NK-cell malignancy (any subtype)
•2. Patient must be ≥ 18 years.
•3. Patients will have provided written Informed Consent.

Exclusion Criteria

•1\) Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent.

Locations (9)

Bedfordshire Hospitals NHS Foundation Trust

Bedford, Bedfordshire, United Kingdom

Portsmouth Hospitals University NHS Trust

Portsmouth, Hampshire, United Kingdom

University Hospital Southampton NHS Foundation Trust

Southampton, Hampshire, United Kingdom

Wye Valley NHS Trust

Hereford, Herefordshire, United Kingdom

University Hospitals of Leicester NHS Trust

Leicester, Leicestershire, United Kingdom

Norfolk and Norwich University Hospitals NHS Foundation Trust

Norwich, Norfolk, United Kingdom

Nottingham University Hospitals NHS Trust

Nottingham, Nottinghamshire, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, Oxfordshire, United Kingdom

The Newcastle Upon Tyne Hospitals NHS Foundation Trust

Newcastle upon Tyne, Tyne and Wear, United Kingdom

Key Dates

Start Date

March 11, 2021

Primary Completion Date

October 31, 2022

Completion Date

January 31, 2024

Last Updated

February 6, 2024

Enrollment

592

ACTUAL participants

Conditions

Classical Hodgkin LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal B Cell LymphomaHigh-grade B-cell LymphomaBurkitt LymphomaFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLymphoplasmacytic LymphomaNodular Lymphocyte Predominant Hodgkin LymphomaPeripheral T-cell Lymphoma

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

B-cell MalignancyMarginal Zone Lymphoma+7 more

View study

RECRUITINGPHASE1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Non-hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 6, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Inclusion Criteria

Exclusion Criteria

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL